Actimmune® (interferon gamma-1b), under Phase III clinical trial has been found not significantly beneficial in patients with idiopathic pulmonary fibrosis (IPF) compared to placebo – enough for the study’s independent data monitoring committee (DMC) to recommend discontinuation of the trial.
The Phase 3 INSPIRE clinical trial was a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Actimmune® in IPF patients with mild to moderate impairment in lung function – with survival time as the primary endpoint.
Marketed by InterMune, Inc. (Nasdaq: ITMN) for the treatment of two life-threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis, Actimmune® is a synthesized version of interferon gamma - a naturally occurring protein believed to stimulate the immune system.
Find more details from the press release.
Comment Preview